Coxibs and the endothelium**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.  by Verma, Subodh & Szmitko, Paul E
EDITORIAL COMMENT
Coxibs and the Endothelium*
Subodh Verma, MD, PHD,
Paul E. Szmitko, BSC
Toronto, Canada
In this issue of the Journal, Title et al. (1) present the results
of the much-awaited randomized double-blind evaluation
of rofecoxib on endothelial function in patients with coro-
nary artery disease (CAD). From a cardiovascular stand-
point, cyclooxygenase-2 (COX-2) inhibitors have been the
topic of much discussion, debate, and trepidation (2–5).
Mechanistically, the concern about the use of these agents
stemmed from observations suggesting that under physio-
logic conditions COX-2 is a major source of endothelium-
derived prostacyclin (PGI2) and that selective blockade of
COX-2 may result in a disproportionate and unopposed
increase in COX-1–derived thromboxane (TXA2) (an
endothelium-derived contracting factor and prothrombotic
molecule) relative to PGI2. Such an imbalance might favor
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endothelial dysfunction and uncover a prothrombotic phe-
notype. Although an attractive hypotheses, in healthy vol-
unteers rofecoxib administration was associated with no
effect on endothelium-dependent or -independent vasomo-
tion (6). However, healthy volunteers may be less suscepti-
ble to the effects of a potential imbalance between PGI2 and
TXA2 compared with patients with CAD in whom de-
creased basal production of nitric oxide may serve to
exaggerate this relative imbalance. Surprisingly, the first
preliminary evaluation of this concept revealed that coxib
treatment in patients with severe CAD was associated with
an improvement in endothelial function and an associated
decrease in C-reactive protein (CRP) levels (7), a powerful
risk marker and mediator of inflammation and athero-
thrombosis (8–10). Title et al. (1) report the randomized
evaluation of coxib therapy on endothelial function and
inflammation in patients with angiographically proven
CAD, which suggests that rofecoxib neither improves nor
adversely affects endothelial function or inflammatory
marker production during an eight-week treatment period.
Endothelial function: a biomarker for vascular risk.
Dysfunction of endothelial cells is probably the earliest
event in the process of lesion formation and hence the
concept that assessment of endothelial function may be a
useful prognostic tool for CAD (11). Coronary endothelial
cell perturbations often are reflected in peripheral vasodila-
tor abnormalities, thereby allowing the assessment of pe-
ripheral endothelial function as a measure of coronary
vasomotion (12). The interest in endothelial function test-
ing is based on the premise that: 1) the healthy endothelium
is nonthrombogenic; 2) endothelial dysfunction occurs in
response to vascular risk factors and is an early event in
atherosclerosis; 3) endothelial dysfunction precedes struc-
tural atherosclerosis; 4) interventions that improve endothe-
lial function also decrease cardiovascular events in patients
with stable coronary disease; 5) reproducible, noninvasive
assessments of endothelial function exist; and 6) endothelial
function testing fulfills the criteria for an acceptable biomar-
ker (11).
Recent studies also suggest that there is a correlation
between endothelium-dependent vasodilation and CRP lev-
els (13). C-reactive protein is a powerful independent
predictor of myocardial infarction (MI), stroke, and vascular
death in a variety of settings (8–10) and appears to be a
better prognosticator of cardiovascular events than low-
density lipoprotein (LDL) cholesterol (10). Over the past
few years, much interest has been generated into unraveling
the mechanistic basis of the CRP-atherosclerosis connec-
tion. Indeed, recent studies, including work from our
laboratory, suggest that CRP not only is a predictor but also
a mediator of lesion formation (14–23). C-reactive protein,
at concentrations known to predict vascular disease, has a
direct effect in stimulating diverse early atherosclerotic
processes, including endothelial cell adhesion molecules,
chemoattractant chemokines, and macrophage LDL up-
take. In addition, CRP directly modulates the production of
endothelium-derived vasoactive factors, including down-
regulating endothelial nitric oxide synthase-derived nitric
oxide while augmenting production of the potent
endothelium-derived vasoconstrictor endothelin-1. Addition-
ally, CRP facilitates endothelial cell apoptosis and attenuates
angiogenesis, which is an important compensatory mechanism
in ischemia. More recently, CRP has also been demonstrated
to promote the release of plasminogen activator inhibitor-1
from endothelial cells, upregulate angiotensin-mediated neo-
intimal formation, and alter endothelial progenitor cell
survival and differentiation (14–23).
Invasive and noninvasive endothelial vasomotion testing
appears to have prognostic value in diverse patient popula-
tions and in response to a variety of cardiovascular risk
factors (11,24–30). Although large-scale validation of this
concept is currently underway (31), the balance of published
information thus far supports the notion that vasomotion
assessment reflects endothelial cell dysfunction or integrity
in vivo.
COX-2, endothelial function, and cardiovascular risk.
There is considerable debate as to whether COX-2 is
proatherogenic or antiatherogenic in nature. In support of a
prothrombotic role of COX-2 are concerns that COX-2
blockade causes a relative imbalance of PGI2 and TXA2,
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which theoretically could uncover a prothrombotic and
proatherosclerotic phenotype (32). Indeed deletion of PGI2
in mice exaggerates vascular injury, supporting the role of
PGI2 in vascular homeostasis (33). However, it is important
to note that COX-2 blockade does not mimic a PGI2
deletion in vivo because COX-2 blockade still allows COX-
1-mediated PGI2 production to occur. The cardiovascular
safety of COX-2 inhibitors have been questioned by other
experimental studies demonstrating that COX-2 is impor-
tant for the late phase of ischemic preconditioning (34) and
that celecoxib increases the risk of thrombosis in canine
models of vascular injury (35). More recently, COX-2
blockade was demonstrated to increase atherosclerosis in
apoE-deficient mice, casting further doubt on the cardio-
vascular effects of coxibs (36). From a clinical standpoint,
much controversy surrounds the observations of athero-
thrombotic risk of coxibs in the Vioxx Gastrointestinal
Outcomes Research (VIGOR) trial (37), and the retrospec-
tive analysis reported by Mukherjee et al. (5). It is important
to note that meta-analysis of all rofecoxib studies have not
uncovered any prothrombotic effect of this COX-2 blocker
(38). More recently, in a large population-based retrospec-
tive analysis from Ontario, Canada, no increase in short-
term risk of MI was found with the use of selective COX-2
blockers in the elderly population (39). In healthy patients,
short-term rofecoxib treatment was demonstrated to have
no adverse effect on endothelial function (6) and actually
improved endothelial function in patients with severe ath-
erosclerosis (7). In yet another recent study, healthy men
were randomized to receive a seven-day treatment with
rofecoxib (50 mg/day), naproxen (1,000 mg/day), aspirin
(75 mg/day), or diclofenac (150 mg/day) and formation of
thromboxane, prostacyclin, and thrombin in the bleeding-
time blood at the site of standardized microvascular injury
was assessed before and after treatment. Rofecoxib had no
effect on any variables measured (40). At the other end of
the spectrum are intriguing data that COX-2 inhibitors
might actually be antiatherogenic. Preliminary evidence
suggests that celecoxib lowers CRP levels, which are a
powerful marker of future cardiovascular events, and reduces
oxidative stress in patients with CAD (7). Furthermore,
meloxicam, a preferential COX-2 blocker, was associated
with significant reductions in adverse outcomes in acute
coronary syndrome patients (41). The enzyme COX-2 is
markedly upregulated in atherosclerotic plaques (42,43)
and, indeed, in LDL receptor-deficient mice, rofecoxib
treatment is associated with reduction in atherosclerosis
despite an imbalance between PGI2 and TXA2 (44). The
COX-2 blockers, including rofecoxib, have been demon-
strated to be beneficial after acute experimental MI (45,46).
Clearly, as the debate between the experimental and clinical
evidence continues, it is important to realize that until a
large-scale randomized controlled trial with hard end points
(MI, stroke, and cardiovascular death) is conducted we will
not have a definitive answer as to whether coxibs are neutral,
promote atherothrombosis, or are actually antiatherogenic.
The study by Title et al. (1) demonstrates in a double-
blind, placebo-controlled, parallel design fashion, that
eight-week treatment with rofecoxib in patients with estab-
lished CAD neither adversely affects endothelium-
dependent or -independent vascular function nor alters
inflammatory biomarker profiles (CRP, soluble intercellular
adhesion molecule, and soluble interleukin-6 receptor).
Although these data suggest that in patients with known
atherosclerosis there may be no detrimental effect of rofe-
coxib therapy on endothelial function and inflammatory
profile, a number of important points need to be considered
in evaluating these data. First, the study contrasts that
recently published by Chenevard et al. (7) demonstrating a
beneficial effect of celecoxib on endothelial function and
CRP in patients with atherosclerosis. As acknowledged by
the authors, these differences may be related to sample size
or may actually reflect a difference between celecoxib and
rofecoxib. Second, there appears to be an imbalance in
baseline angiotensin-converting enzyme inhibitor (ACE)
use between the two groups (p  0.07). Given the powerful
effects of ACE inhibitors on vascular function, this remains
an important limitation. Third, the lack of effect of rofe-
coxib on inflammatory biomarkers and endothelial function
may reflect the high background use of statin and ACE
inhibitors in the two groups, in addition to low-dose aspirin.
Although these agents can directly modulate endothelial
function, these are proven contemporary treatments for
patients with established CAD, and the study in this regard
mimics the real-life scenario. Fourth, the authors failed to
uncover a relationship between inflammatory markers and
flow-mediated dilation over time, a relationship that has
been demonstrated by other studies (13). Fifth, the study
was powered primarily to detect a difference in flow-
mediated dilation and not biomarker production. Given the
variability in the results presented for the biomarkers, a
considerably larger sample size may have been required to
determine changes in CRP in response to coxib therapy.
Lastly, it is important to note that these results apply to
patients who were taking low-dose aspirin concomitantly,
and the presence of low-dose aspirin may prevent the
potential imbalance between PGI2 and TXA2. Again, one
of the limitations of the study is the lack of data on PGI2
and TXA2, a critical point in the debate of COX-2
inhibitors and vascular function. Notwithstanding these
criticisms, the study by Title et al. (1) is a very important
addition to the clinical data on coxibs and cardiovascular
risk, which suggests that rofecoxib does not adversely affect
endothelial function or CRP in patients with known coro-
nary atherosclerosis and on background aspirin therapy.
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